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PENILAIAN PENGUBAHSUAIAN SENDIRI DALAM PENGAMBILAN 
UBAT PENGIKAT FOSFAT MENGIKUTI KANDUNGAN FOSFAT DALAM 
MAKANAN UNTUK PENGURUSAN HIPERFOSFATEMIA DALAM 
KALANGAN PESAKIT HEMODIALISIS DI PULAU PINANG, 
MALAYSIA 
 
ABSTRAK 
Hiperfosfatemia ialah satu masalah serius yang menyebabkan kadar kematian 
yang tinggi dalam kalangan pesakit dialisis. Banyak kajian telah menunjukkan 
bahawa dialisis dan kawalan makanan sahaja tidak dapat menguruskan masalah 
hiperfosfatemia. Justerus itu, ubat pengikat fosfat biasanya diperlukan oleh pesakit 
dialisis. Kaunseling makanan yang sediada untuk mengamalkan diet rendah fosfat 
didapati tidak memberi kesan yang nyata untuk mengawal paras fosfat pesakit. Oleh 
itu, kajian ini dilakukan untuk menilai keberkesanan buku kecil intervensi baru yang 
melibatkan 80 makanan yang biasa dimakan oleh pesakit hemodialsis di Pulau 
Pinang untuk pengubahsuaian sendiri bagi ubat pengikat fosfat mengikuti kandungan 
fosfat dalam makanan. Terdapat 117 orang pesakit hemodialisis dari 8 unit dialisis di 
Pulau Pinang telah dipilih untuk menyertai kajian ini. Mereka dibahagikan secara 
rawak kepada kumpulan intervensi dan kumpulan standard. Pesakit-pesakit daripada 
kedua-dua kumpulan telah menerima kaunseling makanan yang sama tentang diet 
rendah fosfat secara individu, sedangkan kumpulan intervensi diberi satu kaunseling 
tambahan tentang pengubahsuaian sendiri untuk ubat pengikat fosfat. Paras fosfat 
telah diukur pada permulaan kajian, bulan ke-3, bulan ke-6 and bulan ke-9 bagi 
kedua-dua kumpulan. Keberkesanan cara pengubahsuaian sendiri ubat pengikat 
fosfat terhadap jumlah pengambilan kalori, protein dan fosfat; kepuasan terhadap 
makanan; dan pematuhan terhadap pengambilan ubat pengikat fosfat juga diukur 
xiv 
 
pada permulaan dan pada akhir kajian ini. Analisis statistik telah dijalankan dengan 
mengunakan SPSS melalui cara "repeated measured ANOVA",  "independent t-test" 
and "pair t-test" bagi data yang bertaburan normal. Di samping itu, Wilcoxon dan 
Mann Whitney digunakan untuk data yang tidak bertaburan normal. Analisis 
menunjukkkan penurunan yang ketara untuk purata paras fosfat bagi kedua-dua 
kumpulan selepas kajian. Walau bagaimanapun, kumpulan intervensi menunjukkan 
penurunan paras fosfat yang lebih nyata (2.15±0.22 mmol/L ke 1.68±0.43 mmol/L) 
dalam tempoh yang lebih singkat (3 bulan) berbanding dengan kumpulan standard. 
Di samping itu, ia menunjukkan penambahan skor untuk kepuasan terhadap makanan 
and pematuhan terhadap pengambilan ubat pengikat fosfat untuk kumpulan 
intervensi jika dibandingkan dengan kumpulan standard (p<0.05). Walau 
bagaimanapun, ia tidak terdapat perbezaan yang nyata untuk jumlah pengambilan 
kalori, protein and fosfat untuk kedua-dua kumpulan sebelum dan selepas kajian. 
Kesimpulannya, konsep pengubahsuaian sendiri bagi ubat pengikat fosfat mengikuti 
kandungan fosfat dalam makanan memberi kesan yang positif dalam penurunan 
paras fosfat, kepuasan terhadap makanan dan pematuhan terhadap pengambilan ubat 
fosfat dalam kalangan pesakit hemodialisis. 
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EVALUATION ON SELF-ADJUSTED PHOSPHATE BINDER 
ADMINISTRATION TO DIETARY PHOSPHATE CONTENTS IN 
MANAGEMENT OF HYPERPHOSPHATEMIA AMONG HEMODIALYSIS 
PATIENTS IN PENANG, MALAYSIA 
 
 
ABSTRACT 
 Hyperphosphatemia is a serious problem that is associated with high mortality 
rate among the dialysis patient. Many studies have revealed that the dialysis and 
dietary restriction are insufficient for managing hyperphosphatemia. Thus, phosphate 
binder is usually required for the dialysis patients. Current diet counseling on low 
phosphate diet did not effectively lower the phosphate level. Therefore, this study 
was designed to evaluate the effectiveness of a newly intervention booklet that 
contains 80 common eaten foods that allowed the Penang hemodialysis patients to 
self-adjusted phosphate binder administration to their dietary phosphate content. A 
total of 117 of hemodialysis patients from 8 dialysis centers in Penang state were 
recruited for the study. They were randomly divided into intervention and standard 
groups. All the participants from both groups went through the same diet counseling 
on low phosphate diet individually but the intervention group was given an extra 
counseling on the self-adjusted phosphate binder. The phosphate level was measured 
at the baseline, month 3, month 6 and month 9 for both of the groups. The effect of 
the self-adjusted phosphate binder to the total calories, protein, phosphate intake; 
food satisfaction; and phosphate binder adherence were measured at the baseline and 
at the end of the study. Statistical analysis was carried out by using SPSS with the 
method of repeated measured ANOVA, independent t-test and paired t test for data 
that normally distributed while the Wilcoxon and Mann Whitney for data that was 
xvi 
 
not normally distributed. The analysis showed significant reduction of mean 
phosphate level for both groups. However, the intervention group showed significant 
reduction (2.15±0.22 to 1.68±0.43 mmol/L) with shorter time period (3 month) 
compare to the standard group. Furthermore, there were significant higher increment 
of the score for food satisfaction and phosphate binder adherence in the intervention 
group as compare to the standard group (p<0.05). However, there were no significant 
change in total calories, protein and phosphate intake for both groups before and 
after the study. In conclusion, the self-adjusted phosphate binder to dietary phosphate 
intake concept gave a positive impact on lowering the serum phosphate level, food 
satisfaction and phosphate binder adherence in hemodialysis patients.  
 
 
 
 
 
 
 
 
 
  
CHAPTER 1 
INTRODUCTION 
 
 
1.1   Hyperphosphatemia in Chronic Kidney Disease (CKD) 
 
Hyperphosphatemia is a serious and pervasive problem which will lead to 
secondary hyperparathyroidism, renal osteodystrophy and vascular calcification 
among CKD patients (Block et al., 2004; Cannata-Andia & Rodriguez-Garcia, 2002; 
Coladonato, 2005). Numerous studies have demonstrated increased risk of morbidity 
and mortality due to the consequences of hyperphosphatemia (Block et al., 2004; 
Kuhlmann, 2006).  Therefore, prevention and correction of hyperphosphatemia has 
become a major goal of treatment for the kidney failure patients. The recommended 
control target for the phosphate level at 0.8 – 1.45 mmol/L should be achieved to 
reduce the mortality rate among these patients (Kok, Ghazalli, Ching, Fan, & Liew, 
2013). 
 
Phosphate control in CKD patients can be achieved by 3 methods: i) phosphate 
removal by dialysis, ii) restriction of dietary phosphorus intake and iii) inhibition of 
gastrointestinal phosphorus absorption by using phosphate binder (PB) (Kuhlmann, 
2006). Despite follow the dialysis schedule and adjust the dialysis parameters to 
improve the phosphorus removal, majority of the CKD patients still need to follow 
the diet restriction on phosphate intake and required PB to achieve the target 
phosphate level (Cannata-Andia & Rodriguez-Garcia, 2002).  
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High phosphate level commonly happens in dialysis patients especially when 
they are well nourished (Chiu et al., 2009). This is because the high protein food has 
high content of dietary phosphorus (Uribarri, 2009). If patients follow the Chronic 
Kidney Disease Guideline’s recommendation of 1.0g – 1.2g protein/ kg body weight, 
the total phosphorus intake would be exceed the recommendation of less than 
1000mg phosphate per day.  Generally, this total phosphate intake is hardly to be 
remove by the 3 time per week; 4 hours dialysis schedule alone (Uribarri & Calvo, 
2003). Therefore, the use of PB and restriction of total dietary intake of phosphate 
others than from high protein food like phosphate additive were crucial in achieving 
the target phosphate level among the dialysis patient (Cannata-Andia & Rodriguez-
Garcia, 2002).  
 
However, poor adherence to PB prescription is commonly happening due to pill 
burden (Chiu et al., 2009; Kuhlmann, 2006). Generally, the dialysis patients use 
many pharmacological agents to treat, correct or prevent concomitant disease 
(cardiac disease, high cholesterol, bone disease, endocrine disorders) or symptoms 
(sleeping disorder, restless legs, gastrointestinal discomfort). Studies revealed that 
49% of the total oral medications (with an average range of 10-14 drugs daily) that 
used by the dialysis patients was PB (Chiu et al., 2009; Kuhlmann, 2006). According 
to the authors, this large amount of medications intake causes the patients skipped the 
PB intake (Chiu et al., 2009). Hence, prescribing a larger number of PB might not be 
an appropriate solution to hyperphosphatemia. It was more important to avoid PB 
dosing error than prescribe more PB to the patients. The PB dose should be taken 
respectively to the total amount of phosphate intake in each meals and snack (Chiu et 
al., 2009). 
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Besides the PB non adherence, the hidden phosphate additive in the processed 
food is another challenge for dialysis patient to achieve the target phosphate level. 
Phosphorus is the main component of many preservatives and additives salts in 
processed foods (Uribarri & Calvo, 2003). The processed meat and poultry products 
are shown to have almost 2-3 fold increase in phosphorus content as reported in food 
composition (Uribarri & Calvo, 2003). Normally, the dialysis patients have reached 
the upper limit of total daily phosphate intake due to the high protein food intake. 
Thus, the extra phosphate load from food additive will easily lead to the failure in 
phosphate control (Uribarri, 2009). Therefore, the dialysis patients need to avoid 
processed food to have better control of phosphate level. 
 
Unfortunately, the dialysis patient’s daily life is struggled with dietary restriction 
as well as poor appetite and sometime lack of energy to cook. They will chose to 
consume the processed foods which are very accessible, tasty, and cheaper than fresh 
and unprocessed healthy food (Noori, Kamyar Kalantar-Zadeh, et al., 2010).  
Generally, these processed foods require very little or no preparation and relatively 
with cheaper price at most of the places. All these processed foods together with high 
protein diet have further caused the difficulty for dialysis patients in achieving the 
recommendation of taking less than 1000 mg daily phosphate intake. Thus, this 
excessive phosphate intake causes the prescribed PB dose become inadequate to 
inhibit the phosphate absorption (Blaine, Chonchol, & Levi, 2014). 
 
Indeed, more than 90%- 100% of the phosphorus additive is believed to be 
absorbed in the intestinal tract, as opposed to only 40-60% of intestinal phosphorus 
absorption from animal protein and 10- 30% from vegetarian protein (Kalantar-
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Zadeh et al., 2010; N. Noori et al., 2010). This high bioavailability of phosphate 
additive has further increase the risk of phosphate burden among dialysis patients. 
Besides, there is lack of information on the type and the amount of phosphate 
additive that is added to the processed food. The manufacturers do not require 
reporting the phosphate additives in the food label (Kalantar-Zadeh et al., 2010). 
Consequently, patients have no way to know the type and the amount of phosphate 
additives that are added to the processed food. 
 
 
1.2   Problem Statement 
 
 According to the 21th Report of the Malaysian Dialysis & Transplant 
Registry in 2013, only 27% of peritoneal dialysis (PD) patients and 15% of 
hemodialysis (HD) patients achieved the target phosphate level (0.8 -1.45 mmol/L). 
A total of 45% HD patients and 30% PD patients had phosphate level of more than 
1.8 mmol/L (Kok et al., 2013). Most of these patients were prescribed with PB and 
calcium carbonate remains as the main PB for both HD (92%) and PD patients (85%) 
(Kok et al., 2013).    
 
 The routine management of hyperphosphatemia in most of the dialysis center 
in Malaysia is dietary and phosphate binder’s intake education by the dialysis 
center’s staff nurse. There is usually no dietitian or pharmacist in the dialysis center. 
Thus, dietary and PB intake education by dietitian or pharmacist are limited. 
Generally, patients will be given a list of high phosphate content foods and also a list 
of substitution food items with low phosphate content. They are informed to avoid 
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the high phosphate food by compliance with the low phosphate foods intake. 
Meanwhile, there is very limited education on the correct timing and texture to 
consume the PB. The patients will only have chance to get a proper counseling when 
they are admitted to the hospital where the dietitian and pharmacist are available. 
 
 In Germany, there was a recent developed innovative Phosphate Education 
Program (PEP) concept that was based on eye-estimation of the meal phosphorus 
content by a newly defined phosphate unit (PU) where 1 PU is equivalence to 100 
mg phosphorus. Sixteen pediatrics with CKD were recruited in the study and they 
were educated for self- adjust PB dose based on their own meal’s phosphorus content 
with individually prescribed PB/PU ratio (PB pills per PU) (Ahlenstiel, Pape, Ehrich, 
& Kuhlmann, 2010).  The study revealed that the PEP concept helped the dialysis 
patients to control their phosphate level more effectively where it reduced mismatch 
of the PB dose to the dietary phosphate content.   
 
 However, the investigators in the above mentioned study did not consider the 
intestinal phosphate absorption and also the phosphate additive content in the food. 
They only considered the food from the same food group which had similar 
phosphate content (for instance, a 150 g serving size of any meat sort = 3 PU) 
(Ahlenstiel et al., 2010). Furthermore, to the best of our knowledge, currently no 
study had been conducted in adult dialysis patients on the use of self- adjust PB 
dosage to dietary phosphorus intake by individually prescribed PB/PU ratio. 
Therefore, there is a need to create a friendly self-adjust PB booklet (SPB) for better 
controlling of the phosphate level among the dialysis patients. The Phosphate Unit 
(PU) to meal phosphorus content that consider the intestinal phosphorus absorption 
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of inorganic phosphate additive and the organic phosphorus in natural food should be 
developed from the common eaten foods by the dialysis patients in the local setting. 
The tool will allow greater dietary flexibility, increase food satisfaction & reduce pill 
burden of PB for the dialysis patients.  
 
 A SPB was developed in the present study by using the idea of PEP concept. 
The SPB had more detail with the inclusion of the commonly eaten Malaysian’s food 
(including processed/convenient food) with descriptive & common food measures. 
The food list was fitted to the number of PB tablets to be taken which was based on 1 
PB = 100 mg intestinal absorption of phosphate. The phosphate content was adjusted 
for the phosphate additive and also the percentage of intestinal phosphorus 
absorption.  All the phosphate food contents were referred to the 4th edition of 
Nutrient Composition of Malaysian Food (Tee E Siong, 1997) and Food Composition 
Guide Singapore (Food Composition Guide Singapore, 2003).  
 
 
1.3   Objectives  
 
1.3.1   General Objective 
 
The primary objective of the study was to determine the effectiveness of the SPB in 
reducing the phosphate level between the intervention group and the standard group 
of hemodialysis patients. 
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1.3.2   Specific Objectives 
 
a) To determine the effectiveness of SPB in managing the corrected calcium, 
calcium phosphate product (Ca x P product), parathyroid hormone (PTH), 
urea, creatinine and albumin level between the intervention group and the 
standard group of the hemodialysis patients.  
b) To evaluate the effectiveness of the SPB on hemodialysis patients’ total daily 
calories, protein and phosphate intake. 
c) To evaluate the effectiveness of the of SPB on hemodialysis patients’ food 
satisfaction 
d) To evaluate the effectiveness of the of SPB on hemodialysis patients’ 
adherence to PB 
 
 
1.4   Significant of the Study  
 
 This study will be significant endeavor in promoting a simple and user 
friendly tool for dialysis patients to control their phosphate level. It also will provide 
an insight to the patient by improving their knowledge and understandings about the 
phosphate binders with phosphate food contents and phosphate additive in 
convenient and processed foods. Subsequently, the rate of patients’ non-adherence to 
PB and high dietary phosphate intake from phosphate additive would be reduced 
with the establishment of the use of SPB. 
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 Besides, the dialysis patients and the dialysis team can easily estimate amount 
of the food and number of PB should be taken to meet the target phosphate level 
without referring to the high phosphate food list.  Lastly, this intervention will be 
beneficial to the dialysis team in the management of hyperphosphatemia and 
reducing the rate of hospitalization due to consequences of hyperphosphatemia.   
 
 
1.5   Operational Terminology Definition 
 
Hemodialysis referred to a process that duplicate the kidney function for kidney 
failure patients in reducing the body’s waste and excessive fluids. This treatment 
usually lasts for four hours and is performed three times a week. During this 
procedure, blood is carried from the patient to a dialyzer (artificial kidney), which is 
a device comprised of thousands of very fine hollow fibers. These fibers create a 
semi-permeable membrane and as blood flows through inside the membrane 
dialysate flows in the opposite direction on the outside, removing impurities and 
excess water and properly adjusting the chemical balance of the blood. The “clean” 
blood is then carried back into the patient. During treatment, patients are connected 
to a dialysis machine and hence their movement is limited. However, they are usually 
positioned in a comfortable chair and may read, write, and watch television or sleep 
(Daugirdas, Blake, Peter G., Ing & Todd S., 2015). 
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Hyperphosphatemia is an abnormal phosphate concentration in the blood. It often 
happens in renal failure patients especially when there is an excessive taking of 
phosphate rich food. Average phosphorus levels should be between 0.81 mmol/L to 
1.45 mmol/L. It causes the abnormal metabolism of calcium, vitamin D and 
parathyroid hormone and which subsequently cause mineral and bone disorder and 
vascular calcification (Cannata-Andia & Rodriguez-Garcia, 2002).    
 
Dietary Phosphate content is referred to the amount of phosphorus which exists in 
the food. Most of the foods contain phosphorus especially in high protein foods like 
meat, fish, egg, bean and dairy products. For dialysis patients, they are not allowed to 
take more than 1000 mg phosphorus daily (Barbara A. Bowman, 2012). 
 
Phosphate binders are the medications used to reduce the phosphate absorption in 
dialysis patients. It is usually taken with their meals and snacks. It works by binding 
the phosphate in the gastrointestinal tract and making it unavailable to the body 
absorption. There are 3 types of phosphate binder: aluminum based, calcium based 
and aluminum/ calcium free (Bellasi, Kooienga, & Block, 2006).  
 
Food satisfaction is the emotions, feelings and their perception on the food that they 
are consumed which is related to social, physical or psychological sensation. This 
information can help to identify the gaps and develop an effective action plan for 
improving the compliance of dialysis patients to renal diet (Vad Andersen & Hyldig, 
2015).   
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Adherence to phosphate binder referred to how well the patients taking their 
phosphate binder as prescribed by clinician with the correct dose and 
recommendation of regimen under limited supervision. There are divided into two 
categories (unintentional and intentional). Unintentional non adherence is defined as 
patients prevented from taking the medication due to barriers beyond their control. 
While the intentional non adherence is the patients decides not to take the PB as 
recommended due to their own beliefs (Petel, Antoniou, & Popat, 2017). 
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CHAPTER 2 
LITERATURE REVIEW 
 
 
2.1   Phosphorus in Human Body 
 
Phosphorus is the second most abundant mineral in human body after calcium 
(Bellasi et al., 2006). It is also an essential element which plays an important role in 
multiple biological processes in the body. An approximately of 700 g to 875 g 
phosphorus is present in the adult body of which 85% is in the skeleton (bone and 
teeth); 14% in the intracellular (soft tissue or blood) and only 1% in the extracellular 
compartment (Figure 2.1) (Moe, 2006; Uribarri, 2007).  
 
In skeleton, phosphate is primarily complexes with calcium in the form of 
hydroxyapatite crystals, the remaining phosphate appear as amorphous calcium 
phosphate (Kooienga, 2007; Penido & Alon, 2012). In intracellular, the phosphorus 
typically exist mainly as organic compounds as phosphate esters and to a lesser 
extent as phosphoproteins and free phosphate ions in the soft tissue and cell 
membranes. Only about 0.001 mmol/L free inorganic phosphate concentration is 
found in cell (Moe, 2006).  
 
In the extracellular fluid, about 10% of phosphorus content is bound to protein, 
75% is complexes to sodium, calcium and magnesium and the remainder (15%) is 
present as inorganic phosphate (Pi) that is freely circulating and measured (Figure 
2.1). Thus, the serum measurement only showed a minor fraction of the total body 
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phosphorus in the human body. It is not always reflecting well of the total body 
phosphorus (Heaney, 2012).  The following calculations are used to convert between 
the phosphate concentrations (Johnson, 2010): 
• 1 mmol of phosphate = 31 mg of elemental phosphorus 
• 1 mmol/L of phosphate = 3.1 mg/dL (or 31 mg/L) or phosphorus 
• 1 mg of phosphorus = 0.032 mmol of phosphate 
• 1 mg/dL of phosphorus = 0.32 mmol/L of phosphate 
 
 
 
 Total body phosphorus        Extracellular phosphorus  
  
 
 
 
 
 
 
 
 
Figure 2.1   Distribution of total body phosphorus (Adapted from Moe, 2006) 
 
Generally, serum phosphate involve with multiple organs and hormones in 
regulating the phosphate balance (phosphate homeostasis) in human body. In usual 
phosphate balance, the dietary phosphate intake is balanced by the phosphate 
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excretion in the urine and feces (Blaine et al., 2014). The normal range of serum 
phosphate for infant is 1.50 - 2.65 mmol/L and 0.80 - 1.45 mmol/L in adults 
(Razzaque, 2011; Shaikh, Berndt, & Kumar, 2008).  
 
The intestinal, kidney and bone are the three important organs involve in 
phosphate homeostasis (Berndt & Kumar, 2009). The main hormones that involve in 
the regulation of serum phosphate are vitamin D, parathyroid hormone (PTH) and 
fibroblast growth factor-23 (FGF23) with its cofactor klotho and sodium-phosphate 
co-transporters (Npt2a,Npt2b,Npt2c) (Barbara A. Bowman, 2012).  Others factors 
that are also involve in regulating the phosphate are diet, time of day, and also the 
age, gender and genetics (Lederer, 2014).   
 
2.2   Phosphate Homeostasis  
 
  For body to maintain the balance of serum phosphate, equilibrium must be 
established between the amount of phosphate in the plasma and in the extracellular 
fluid (Uribarri, 2007). The maintenance of phosphate homeostasis is mainly handled 
by the intestinal, kidney and bone (Lederer, 2014; Moe, 2006). Overall intake and 
excretion is determined by the net balance of ingested and absorbed phosphate from 
diet, excretion and reabsorption of phosphate in the urine or feces; in addition of the 
bone formation and resorption (Berndt, Schiavi, & Kumar, 2005; Robert, Michael & 
Orson, 2013). 
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2.2.1   Intestinal Absorption 
 
Phosphorus exists in an organic form in most of the foods. It is usually found in 
animals or plants protein rich food. It will break down into the inorganic form which 
can be absorbed by the human body. This inorganic phosphorus (Pi) is absorbed in 
small intestinal especially in jejunum and ileum through a passive diffusion along 
with an electrochemical gradient (Bellasi et al., 2006; Uribarri, 2007) and also 
through active transport across the cells under the influence of the vitamin D 
(1α,25(OH)2 D3) and PTH, using the sodium phosphate co-transporter type 2b 
(Npt2b) (Penido & Alon, 2012). The passive diffusion is where the inorganic 
phosphate moves across cell membrane without energy. Its movement is based on the 
concept of the high concentration to an area with lower concentration.  
 
Generally, the passive diffusion happens rather than the active transport process. 
The active transport process only happens when the dietary phosphorus intake is low 
(demands for phosphate are increased) or high (demands for phosphate are 
decreased) (Russell, 2001). The phosphate moves against the concentration gradient 
from a lower concentration to higher concentration of the membrane. All this active 
process needs the Npt2b as a transporter where the Npt2b is regulated by dietary 
phosphate, vitamin D and PTH (Joanne Marks, Debnam, & Unwin, 2010).  
 
Previous studies revealed that when there was a high phosphorus intake, it 
induced a decrease of serum 1,25(OH)2 D level (vitamin D) that lower the number of 
Npt2b production, which reduced the absorption of phosphorus in intestinal and 
balance the serum phosphate concentration in the body (Ferrari, Bonjour, & Rizzoli, 
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2005; Martin, Ritter, Slatopolsky, & Brown, 2005). On the other hand, when there 
are low phosphate intake, the serum 1,25(OH)2 D level will increase and more 
phosphate will be absorbed in the intestinal (Ferrari et al., 2005; Martin et al., 2005).  
 
As mention above, only the inorganic form of phosphate can be absorbed by 
human body. Thus, the dietary phosphate bioavailability of food shows the real 
proportion of the phosphate that enters into the body to have passive diffusion or 
active transport effect (Marks, Debnam, & Unwin, 2013; Uribarri, 2007). Normally, 
there is about 1200 mg/day of phosphorus that we consumed daily but only about 
average of 720 - 960 mg (60 - 80%) of this dietary phosphate is absorbed by the 
intestinal (Figure 2.2).  
 
 
    Phosphorus balance                             85% of phosphate store in bone 
                                                                                                            
                                               
 
 
 
 
 
 
 
 
Figure 2.2   Phosphate homeostasis  
                    (Adapted from Hruska, Mathew, Lund, Qiu, & Pratt, 2008) 
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2.2.2   Kidney Phosphorus Handling 
 
The kidney plays an important role in the phosphate homeostasis. As the 
phosphate is less bound to albumin or protein, it is easily filtered at the glomerulus of 
the kidney (Uribarri, 2007). In normal adults, about 3700- 6000 mg/day of 
phosphorus is filtered by the glomerulus daily. Phosphate is reabsorbed back along 
the nephron, where 75% of the filtered phosphorus will be reabsorbed by the 
proximal tubule; 10% by the distal tubule and 15% is lost in urine (Blaine et al., 
2014; Uribarri & Calvo, 2003). The 15% of the phosphate that excretes in urine is the 
total net amount of the absorbed phosphate from the intestinal (Figure 2.2).  
 
The inorganic phosphate (Pi) reabsorption across the proximal tubule and distal 
tubule is an energy-dependent process that using the sodium phosphate co-
transporters as like in the intestinal. The two co-transporters are sodium phosphate 
co-transporter type 2a and type 2c (Npt2a & Npt2c). Both co-transporters are located 
in the brush border membrane of the renal tubule cell (Lee & Marks, 2015; Prasad & 
Bhadauria, 2013). The amount of Pi reabsorption is depends on the dietary phosphate 
intake or PTH which can change the abundance of these co-transporters in the renal 
tubule membrane cells (Blaine, Weinman, & Cunningham, 2011).  
 
Therefore, when there is a low phosphate intake there will be an increase number 
of Npt2a and Npt2c level in the brush border. It gives a result in increasing the Pi 
absorption from the urine. Whereas, the high phosphate intake decrease of these 
abundance of co-transporters leads to reduce the phosphate reabsorption and result in 
a high phosphate in urine (phosphaturia) and more phosphate will be excrete out 
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from the body (Amatschek, Haller, & Oberbauer, 2010). Generally, the dietary 
phosphate or PTH can rapidly changes the insertion or removal of the Npt2a (within 
minutes to hours) and Npt2c (within hours to days) from the brush border of tubule 
membrane cell to balance the serum phosphate concentration (Blaine et al., 2011; 
Razzaque, 2011; Reddi, 2014). Thus, the kidney is an important organ in phosphate 
homeostasis process.  
 
2.2.3   Bone Remodeling 
 
Bone remodeling is a lifelong continuously active process where the old bone is 
removed from skeleton and the new bone is formed through a matrix mineralization 
(Seeman, 2009). The process involves two principles cell types: the bone 
reabsorption (bone breakdown and release calcium and phosphate from the bone 
tissue to the blood) by osteoclasts and bone deposition (forming new bone tissue) by 
osteoblasts (Rucci, 2008). When the bone reabsorption is faster than the bone 
deposition, the bone will becomes more fragile and expose to bone fractures. 
 
There are two main relation of the phosphorus to the bone. Firstly, the inorganic 
phosphate is one of the two main components that require for hydroxyapatite 
formation. Eighty five percent of the total body phosphorus are used to form the 
crystalline hydroxyapatite, Ca10(PO4)6(OH)2 in the bone (Nandeesh, 2012).  
Secondly, the serum phosphate concentration seems to be affecting the osteoblast and 
osteoclast function by 3 hormones (PTH, calcitonin, and vitamin D) with another 2 
target organs which are kidney and GI tract to balance the phosphate concentration in 
the body (Heaney, 2012).  
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In brief, the elevated of PTH can increase the number of osteoclasts for bone 
reabsorption to increase the serum calcium and phosphate while the elevated of 
vitamin D increase the absorption of calcium and phosphate in the intestinal tracts. 
When the calcium is high, the PTH will decrease and it will increase the calcitonin to 
reduce the osteoclast activities (Ahtur & Hall, 2006).   
 
2.3   Phosphorus Homeostasis in Chronic Kidney Disease  
 
 Phosphate metabolism disorder is the most common complication in CKD 
patients. Level of phosphate is usually above the normal range in most of the CKD 
patients once their GFR is less than 15-30 ml/min (Hruska et al., 2008). The impaired 
kidney has cause reducing of renal phosphate excretion. It also reduces the calcitriol 
production when there is insufficient renal mass for 1-α-hydroxylase activity. 
Besides, it also causes an increase of PTH and FGF 23 (Craver et al., 2007). Figure 
2.3 below showed the pathways of the disordered phosphate metabolism. 
 
Generally, the hyperphosphatemia rarely occur in the early stage of CKD; there 
are only less than 10% of patients in stage 3 CKD show high level of phosphate. 
Majority of them achieve the normal phosphate level with an abnormal GFR due to 
the compensation of elevated FGF23 (Martin, David, & Quarles, 2012). Study 
showed that the FGF23 rises progressively as early as CKD stage 2 to 3. It was 
produced by osteoblasts in the bone and its concentration rise with a decline of GFR 
(Lopez et al., 2011).  
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 Figure 2.3   Phosphate metabolism disorder in early stage of CKD  
                     (dashed lines indicate counter regulatory pathway  
                     (Adapted from Kevin J. Martin & González, 2011). 
 
 
 
The elevated FGF23 decreases the proximal tubule phosphate reabsorption in the 
kidney and increased the phosphate excretion in the urine. It also suppresses the 
calcitriol synthesis and lowering the effect of Npt2b co-transporter to decrease the 
intestinal phosphate absorption from the diet (Inoue et al., 2005; Shimada et al., 
2004). Besides that, the reduction of calcitriol by the FGF23 also led to the reduction 
of calcium absorption and stimulates the PTH secretion (Cheng, Kuro-o, & 
Razzaque, 2011; Spiegel & Brady, 2012).  
 
The elevated PTH will then decrease the abundance of Npt2a and Npt2c in renal 
proximal tubule and further reduce the phosphate renal reabsorption (Hill et al., 
2013; Martin, Ritter, Slatopolsky & Brown et al., 2005). Indirectly, it increases the 
Low eGFR 
High serum 
phosphate 
Increase of 
FGF 23 
Decrease of 
1,25(OH)2 D 
(calcitriol) 
Increase of 
PTH 
Reduce of suppress effect as kidney function declines 
20 
 
excretion of phosphate to the urine due to lower renal phosphate reabsorption (Ix, 
Shlipak, Wassel, & Whooley, 2010). All these compensatory situations attempts to 
balance the serum phosphate and calcium level in early stage of CKD patients 
(Oliveira et al., 2010). Hence, it explains why the PTH is elevated as early before 
hyperphosphatemia is occurred.  
 
There was a study reported high PTH happened in 60% of patients with stage 3 
CKD, 70% in stage 4 and 90% in stage 5 but less than 10% of stage 3 CKD have 
hyperphosphatemia (LaClair et al., 2005). These data had proofed that the elevated 
FGF23 had combat the rise of the serum phosphate as GFR falls. However, as the 
GFR continued to decline, the renal phosphate excretion will reach the maximum 
level leading to persistent hyperphosphatemia. The persistent hyperphosphatemia 
will further increases of the secretion of PTH. Lastly, the prolonged high PTH leads 
to secondary hyperparathyroidism (SHPT) (Bergwitz & Jüppner, 2012).  
 
The SHPT with low calcitriol level will then stimulates the bone resorption and 
cause further increased of serum calcium and phosphate concentration (Lorenz-
Depiereux et al., 2006). If the bone remodeling system did not accommodate the 
increase of serum phosphate concentration, the serum phosphate can interact with 
calcium and cause calcification in the blood vessel, heart valves, myocardium and 
others soft tissues which can cause high risk of mortality among these patients 
(Block et al., 2004; Janigan, Hirsch, Klassen, & MacDonald, 2000; Kestenbaum et 
al., 2005; Marco et al., 2003; Saliba & El-Haddad, 2009; Young et al., 2005). 
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In conclusion, the normal serum phosphate level happens in early stage of CKD. 
There will be net zero balance of serum phosphate even though there is excess of 
phosphate in CKD patients compare to healthy individuals (Huang & Moe, 2013). 
With the gradual fall of GFR, the decrease in renal excretion cause positive 
phosphorus balance which will further stimulates elevated of the PTH and develops 
SHPT (Bolasco, 2009; Levin et al., 2006). The SHPT can be occurring before the 
hyperphosphatemia is present. The overt hyperphosphatemia is increase when both 
FGF23 and PTH are no longer sufficient to maintain the zero phosphate balance 
(Yamada et al., 2015). 
  
2.4   Consequences of Hyperphosphatemia in CKD  
 
Hyperphosphatemia is a key factors that cause the hyperthyroidism, mineral 
bone disease (Martin & González, 2011), vascular calcification (Achinger & Ayus, 
2006), left ventricular hypertrophy and cardiovascular mortality in CKD patients 
(Goodman et al., 2000; Hsu & Wu, 2009; Oliveira et al., 2010). There are many 
studies contested the claim that cardiac disease was the major cause of death in CKD 
patients (Block, Hulbert-Shearon, Levin, & Port, 1998; Furgeson & Chonchol, 2008; 
Ganesh, Stack, Levin, Hulbert-Shearon, & Port, 2001; Gutierrez et al., 2008; Henry 
et al., 2002; Jean et al., 2009).  
 
 A study conducted by Block et al. was the first study which demonstrated that 
hyperphosphatemia was the main cause of the mortality and morbidity in 
hemodialysis patients (Block et al., 1998). The study revealed that 6% higher 
mortality risk for each of 0.32 mmol/L higher phosphate level. Ganesh et al. also 
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supported the same hypothesis that the hyperphosphatemia and the elevated PTH 
increased the risk of cardiac death (Ganesh et al., 2001). They found 9% higher risk 
of death related to coronary artery disease and 6% higher risk in sudden death with 
only 0.232 mmol/L raised in serum phosphate level in hemodialysis patients.  
 
A more recent meta-analysis on 14 studies and 109,670 CKD patients had 
further supported the evidence of the association between the hyperphosphatemia 
and the mortality in CKD (Palmer et al., 2011). The authors systematically reviewed 
the data from all the cohort studies which had adjusted for confounding factors like 
age, sex, diabetes, kidney function and also duration of dialysis in all-cause mortality. 
The authors demonstrated that the increase of 0.32 mmol/L in phosphate level caused 
the increase risk of mortality by 18%.   
 
Besides that, there were some studies which were looking at the calcification 
risk in the pre-dialysis CKD patients as well (Anand, Lahiri, Lim, Hopkins, & 
Corder, 2006; Kramer, Toto, Peshock, Cooper, & Victor, 2005; Moe & Chen, 2004; 
Toussaint, Lau, Strauss, Polkinghorne, & Kerr, 2008). A study by Tomiyama et al. 
demonstrated that the hyperphosphatemia can cause the endothelial dysfunction 
(thickening or hardening the vessels) in CKD patients even only in stage 2 to 4 
(Tomiyama et al., 2006). The study revealed that the endothelial dysfunction actually 
would also bring to greater risk of renal function decline among these patients. 
 
The endothelial dysfunction was one of the causes of atherosclerosis and 
cardiovascular disease (Di Marco et al., 2008; Shuto et al., 2009). The high 
phosphate level on endothelial cells inhibited the nitrogen oxide production by 
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increasing the reactive oxygen species production and inactive the endothelial 
nitrogen oxide synthase (Takeda et al., 2006). These oxidative stress and reduction of 
nitrogen oxide production further caused the endothelium dependent vasodilation 
impairment in the cardiac and cause atherosclerosis and cardiovascular disease (Di 
Marco et al., 2008; Oliveira et al., 2010; Shuto et al., 2009).  One of these studies 
also highlighted that the endothelium function depletion might also extend to the 
glomerular endothelium in the kidney and brought to the progression of kidney 
failure in these patients (Oliveira et al., 2010).  
 
With all the support from these researches, treating the phosphate earlier even 
before hyperphosphatemia occurs in CKD stage 2 to 4 patients might bring clinical 
benefits and it may help to reduce the early clinical consequences of mineral bone 
disease, endothelial dysfunction and later the vascular calcification. It also might 
slow down the progression of renal failure. There are a few studies which propose to 
initial phosphate control at earlier stages when phosphate retention had begun, as 
shown by elevations in PTH and FGF23 levels, but before the hyperphosphatemia 
occurs (Gutiérrez & Wolf, 2010; Martin & Gonzalez, 2011; Oliveira et al., 2010). 
The studies attempted to show that early phosphate control may help in reducing the 
early mineral and bone disturbance. However, in current clinical practice even in 
Malaysia, the phosphate control are emphasized in ESRD patients who already 
having hyperphosphatemia after dialysis. 
 
Many epidemiology studies had highlighted that majority of the dialysis patients 
had high phosphate level (Eiji Takeda, 2011). Data from the International Dialysis 
and Practice Pattern Study (DOPPS) revealed that less than 50% of the dialysis 
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patients meet the target phosphate level (Young et al., 2000). While in the Malaysia, 
there was only 15% of dialysis patients meet the target phosphate level recommended 
by KDIGO (0.80 to 1.45mmol/L) and 42% of the hemodialysis patients had 
phosphate level more than 1.8mmol/L in 2012 (Kok et al., 2013).  
 
In conclusion, hyperphosphatemia is independent risk factors for endothelial 
dysfunction that cause progression in renal failure and cardiovascular mortality 
CKD. Normalization of phosphate level is urging for reducing these fatal 
consequences as early as at stage 2-4 CKD. However, the evidence for controlling 
the phosphate in early stage of CKD is currently still insufficient to inform clinical 
decision making policy or practice guidelines.  Thus, more investigations should be 
carried out to assess the significance of early control of phosphate level even in the 
stage 2 to 4 CKD patients for better management of hyperphosphatemia. 
 
2.5   Management of Hyperphosphatemia 
 
In clinical practice, the management of hyperphosphatemia is by controlling the 
intake and removal of phosphate from the body. There are 3 main strategies for 
controlling the hyperphosphatemia:  
 
a) Removal of phosphate from adequate dialysis 
 
b) Phosphate binders for minimize the intestinal absorption 
 
c) Restriction of dietary phosphate intake 
 
 
 
